Amgen Can't Halt Sandoz's Biosimilar Launch Ahead Of Appeal

Law360, Los Angeles (April 15, 2015, 6:15 PM ET) -- A California federal judge on Wednesday denied a bid by Amgen Inc. to prevent Sandoz Inc. from launching the first copycat biologic drug approved under the Affordable Care Act while the parties wait for an appeals court decision, ruling that Amgen failed to demonstrate irreparable harm.



California-based Amgen had asked U.S. District Judge Richard Seeborg to grant an injunction restricting the Novartis AG unit from marketing Zarxio, a newly approved version of Amgenâ€™s blockbuster anti-infection drug Neupogen, generically known as filgrastim, pending the outcome of an...

To view the full article, register now.